慢性乙型肝炎停用核苷(酸)类似物后的长期结局:RETRACT-B队列随访
RETRACT-B全球多中心队列纳入2029例病毒抑制、HBeAg阴性、HBsAg阳性的慢乙肝患者,评估停用核苷(酸)类似物后的长期结局。中位随访65个月,10年停药后HBsAg清除率为17%,59%需再治疗;EOT HBsAg<100 IU/ml者10年HBsAg清除率达52%,而≥1000 IU/ml或肝硬化者获益有限。
要点
- 停药后10年HBsAg清除率17%,但59%的患者需要再治疗。
- EOT HBsAg<100 IU/ml者10年HBsAg清除率52%、再治疗率28%。
- HBsAg≥1000 IU/ml或肝硬化患者不建议有限疗程治疗。
核心结论
- 10年停药后HBsAg清除率为17%,超过半数患者需再治疗。
- EOT HBsAg<100 IU/ml者最受益于停药,10年HBsAg清除率52%。
- HBsAg≥1000 IU/ml或肝硬化患者不建议有限疗程治疗。
研究设计与样本
- RETRACT-B全球多中心队列的延长随访研究,纳入2029例病毒抑制、HBeAg阴性、HBsAg阳性的慢乙肝患者。
- EOT时平均年龄52岁,81%为亚洲人,15%白人,4%黑人/其他;EOT平均HBsAg为2.7 log10 IU/ml。
- 中位随访65个月(范围35-99个月)。
主要发现
- 10年停药后HBsAg清除率为17%(EOT HBsAg<100/100-1000/≥1000 IU/ml分别为52%/13%/6%,p<0.001)。
- 59%的患者再治疗(EOT HBsAg<100/100-1000/≥1000 IU/ml分别为28%/62%/71%)。
- 171例HBsAg清除者中9例(5.3%)发生HBsAg血清学逆转,其中6例再次HBsAg清除。
- 10年肝炎发作、肝细胞癌和失代偿风险分别为30%、3.9%和3.3%。
- 有肝硬化史者10年失代偿风险(5.7% vs 3.0%)和肝细胞癌风险(12% vs 2.4%)均更高(p<0.001)。
关键数值与推荐
- EOT HBsAg<100 IU/ml者10年HBsAg清除率52%、再治疗率28%,可考虑有限疗程。
- EOT HBsAg≥1000 IU/ml者10年HBsAg清除率6%、再治疗率71%,不建议有限疗程。
- 有肝硬化史者10年肝细胞癌风险12%、失代偿风险5.7%,不建议有限疗程。
临床怎么用
- 对EOT HBsAg<100 IU/ml且能保证严格监测的患者,可考虑停用核苷(酸)类似物以追求HBsAg清除。
- HBsAg≥1000 IU/ml或肝硬化患者不建议停药,应继续抗病毒治疗。
- 停药后需长期监测,尤其对成功停药5-10年的患者。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Stopping nucleos(t)ide analogues (NAs) in patients with chronic hepatitis B can increase hepatitis B surface antigen (HBsAg) loss rates. However, long-term follow-up (FU) data after NA cessation in a multiethnic population are lacking. This study aimed to assess long-term outcomes after NA cessation in a large global cohort. METHODS: Extended FU data were collected from patients enrolled in the RETRACT-B cohort. New patients were added if they met the inclusion criteria (virally suppressed, HBeAg negative, and HBsAg positive at end of therapy [EOT]). The primary outcome was the 10-year off-treatment HBsAg loss rate. Secondary outcomes were retreatment and adverse events. RESULTS: In total, 2,029 patients were included. At EOT, mean age was 52 years; 81% were Asian, 15% White, and 4% Black/Other. Mean HBsAg at EOT was 2.7 log10 IU/ml (<100/100-1,000/≥1,000 IU/ml: 16/46/38%). Median FU was 65 [range 35-99] months. The 10-year off-treatment HBsAg loss rate was 17% (<100/100-1,000/≥1,000: 52/13/6%, p <0.001) and 59% were retreated (<100/100-1,000/≥1,000: 28/62/71%). HBsAg seroreversion was observed in 9 out of 171 (5.3%) patients, of whom 6 re-lost HBsAg. The 10-year risks of flares, hepatocellular carcinoma and decompensation were 30%, 3.9%, and 3.3%, respectively. A history of cirrhosis was associated with a higher risk of decompensation (10-year: 5.7% vs. 3.0%) and hepatocellular carcinoma (10-year: 12% vs. 2.4%), both p <0.001. CONCLUSION: At 10 years, 17% of patients achieved off-treatment HBsAg loss, whereas more than half were retreated. Patients with HBsAg levels <100 IU/ml benefit the most from NA cessation with a HBsAg loss rate of 52%. Based on our data, finite NA therapy is not recommended if HBsAg is ≥1,000 IU/ml or in patients with cirrhosis. IMPACT AND IMPLICATIONS: Based on our study, we can conclude that finite nucleos(t)ide analogue therapy can be considered in patients with hepatitis B surface antigen (HBsAg) levels <100 IU/ml when aiming for HBsAg loss, since they have the highest likelihood of achieving this endpoint (52%) and the lowest need for retreatment (28%) during long-term follow-up, but only when strict monitoring can be guaranteed. In contrast, finite therapy is not recommended in patients with HBsAg levels ≥1,000 IU/ml or those with a history of cirrhosis, especially as cirrhosis is a known risk factor for hepatic decompensation and hepatocellular carcinoma. In addition, our data can be used to further improve patient monitoring after finite nucleos(t)ide analogue therapy, especially in those who successfully remain off-therapy for 5 to 10 years.
引用
- Dongelmans E, Hirode G, van Bӧmmel F, et al. Long-term outcomes after nucleos(t)ide analogue cessation in chronic hepatitis B - follow-up from the RETRACT-B cohort. J Hepatol. 2026. PMID: 41921700. doi:10.1016/j.jhep.2026.03.030
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。